Press release
VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy Has Been Approved by Zai Lab and Argenx
Demyelinating Polyneuropathy Market
Download Full PDF Sample Copy of Market Report @https://exactitudeconsultancy.com/request-sample/72651
Growing awareness, improved diagnostic capabilities, and expanding research pipelines in immunotherapies and biologics are creating significant opportunities for pharmaceutical and biotechnology companies. By 2034, the market is expected to be a key focus area in neurology and rare disease treatment.
Market Overview
The global demyelinating polyneuropathy market was valued at USD 2.1 billion in 2024 and is projected to reach USD 6.7 billion by 2034, growing at a CAGR of 12.3% during the forecast period.
Key Highlights:
• Market Size 2024: USD 2.1 billion
• Forecast 2034: USD 6.7 billion
• CAGR (2024-2034): 12.3%
• Growth Drivers: Rising incidence of autoimmune disorders, advances in immunotherapy, and improved access to neurology care.
• Challenges: High treatment costs, delayed diagnosis, and limited availability of disease-modifying therapies.
• Leading Players: CSL Behring, Grifols, Takeda Pharmaceutical, Pfizer, Novartis, Sanofi, Teva Pharmaceuticals, and Biogen.
The market is shifting toward precision medicine and novel biologics, with strong clinical pipelines aimed at improving outcomes in CIDP and related disorders.
Segmentation Analysis
By Disease Type:
• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• Guillain-Barré Syndrome (GBS)
• Multifocal Motor Neuropathy (MMN)
• Others (hereditary and rare demyelinating polyneuropathies)
By Treatment Type:
• Intravenous immunoglobulins (IVIg)
• Corticosteroids
• Plasma exchange (plasmapheresis)
• Monoclonal antibodies & biologics
• Small molecules
• Symptomatic treatments (pain management, physiotherapy)
By Route of Administration:
• Intravenous
• Subcutaneous
• Oral
By End-User:
• Hospitals & neurology clinics
• Specialty centers for rare diseases
• Academic & research institutes
• Home healthcare settings
Summary:
IVIg remains the gold standard treatment, but monoclonal antibodies and biologics represent the fastest-growing category, reflecting the shift toward targeted therapies.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72651/demyelinating-polyneuropathy-market
Regional Analysis
North America
• Largest market due to advanced neurology care infrastructure, early adoption of biologics, and supportive reimbursement frameworks.
• The U.S. leads with strong clinical trial activity and patient advocacy organizations.
Europe
• Strong growth in Germany, UK, and France, supported by rare disease funding and national neurology networks.
• EMA approval pathways for orphan drugs drive innovation.
Asia-Pacific
• Fastest-growing region, led by Japan, China, and India.
• Increasing patient awareness, government investments in neurology, and expanding clinical trials fuel growth.
Middle East & Africa
• Gradual adoption, with GCC nations improving neurology services.
• Limited access in lower-income regions, though rare disease initiatives are emerging.
Latin America
• Brazil and Mexico are key contributors, with growing access to immunotherapies and plasma therapies.
Summary:
North America leads, but Asia-Pacific is projected to post the fastest CAGR (13%+), becoming a key hub for clinical trials and therapy adoption by 2034.
Market Dynamics
Key Growth Drivers:
• Rising global prevalence of CIDP and GBS.
• Expanding use of IVIg and plasma therapies.
• Advances in monoclonal antibodies and biologics targeting autoimmune pathways.
• Strong patient advocacy and orphan drug designations for rare neuropathies.
Key Challenges:
• High cost of long-term therapies.
• Underdiagnosis and misdiagnosis due to lack of awareness.
• Limited availability of disease-modifying drugs compared to symptomatic care.
Latest Trends:
• Growing clinical trials of anti-FcRn therapies for CIDP.
• Development of subcutaneous immunoglobulin (SCIg) for home-based treatment.
• Expansion of gene therapy approaches for hereditary neuropathies.
• Increasing collaboration between neurology specialists, biotech firms, and patient groups.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72651
Competitor Analysis
Major Players in the Demyelinating Polyneuropathy Market:
• CSL Behring - Leader in IVIg therapies for CIDP and GBS.
• Grifols - Strong presence in plasma-derived therapies.
• Takeda Pharmaceutical - Active in immunoglobulin and biologics development.
• Pfizer - Expanding pipeline in neurology and rare disease therapeutics.
• Novartis - Focused on immunomodulatory drugs.
• Sanofi - Active in monoclonal antibody-based neurology research.
• Teva Pharmaceuticals - Offering generics and specialty neurology therapies.
• Biogen - Innovating in neuroimmunology and rare neurological disorders.
Competitive Summary:
The market is dominated by companies offering IVIg and plasma therapies, but the competitive edge is shifting toward novel biologics, monoclonal antibodies, and gene therapies. Partnerships, licensing deals, and orphan drug designations will shape future strategies.
Conclusion
The Demyelinating Polyneuropathy Market is projected to grow from USD 2.1 billion in 2024 to USD 6.7 billion by 2034, at a CAGR of 12.3%. As immunology and neurology converge, the market is set to benefit from innovations in biologics, personalized medicine, and rare disease research.
Key Takeaways:
• Market to grow at 12.3% CAGR (2024-2034).
• IVIg remains the backbone therapy, but biologics and monoclonal antibodies are the fastest-growing.
• North America leads, while Asia-Pacific will post the fastest CAGR.
• Competition centers on pipeline innovation, biologics, and patient advocacy partnerships.
• Future opportunities lie in gene therapies, home-based SCIg delivery, and anti-FcRn therapies.
As therapies advance from symptomatic management to disease-modifying interventions, this market will be central to transforming outcomes for patients with debilitating neuromuscular conditions worldwide.
This report is also available in the following languages : Japanese (脱髄性多発神経炎市場), Korean (탈수초성 다발신경병증 시장), Chinese (脱髓鞘性多发性神经病市场), French (Marché de la polyneuropathie démyélinisante), German (Markt für demyelinisierende Polyneuropathie), and Italian (Mercato della polineuropatia demielinizzante), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72651/demyelinating-polyneuropathy-market#request-a-sample
Our More Reports:
Venture Capital Investment Trends in Pharma - Q2 2025 Market
https://exactitudeconsultancy.com/reports/73659/venture-capital-investment-trends-in-pharma-q2-2025-market
Pharma M&A Deals Q2 2025 Market
https://exactitudeconsultancy.com/reports/73660/pharma-m-a-deals-q2-2025-market
Immuno-oncology Market
https://exactitudeconsultancy.com/reports/73661/immuno-oncology-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy Has Been Approved by Zai Lab and Argenx here
News-ID: 4201702 • Views: …
More Releases from Exactitude Consultancy
Information about immune checkpoint inhibitors for colorectal cancer is revealed …
The global Immune Checkpoint Inhibitors Clinical Trials Analysis Market is expanding rapidly as oncology research increasingly focuses on immunotherapy as a frontline treatment for cancer. Immune checkpoint inhibitors (ICIs) target regulatory pathways such as PD-1, PD-L1, and CTLA-4, unlocking the immune system's ability to fight tumors. With their proven success in melanoma, lung, kidney, and head & neck cancers, ICIs represent one of the most transformative developments in modern oncology.
Download…
A new Myeloid Cell Targeting Therapeutics participant joins the clinic | ApexOnc …
The global Myeloid Cell Targeting Therapeutics Market is gaining significant traction as immuno-oncology research increasingly recognizes the role of myeloid cells in cancer progression, immune evasion, and chronic inflammation. Myeloid cells-including macrophages, dendritic cells, and myeloid-derived suppressor cells (MDSCs)-play dual roles: while essential for immune defense, they also contribute to tumor growth and resistance to therapies when dysregulated.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72647
Targeting these cells with…
Cell and Gene Therapy Market : Transforming the Future of Medicine
Introduction
Cell and gene therapies (CGT) represent one of the most revolutionary shifts in modern healthcare, offering the potential to cure diseases at their genetic and cellular roots rather than simply managing symptoms. By repairing, replacing, or regenerating diseased cells and tissues, these therapies provide hope for conditions once considered incurable - from rare genetic disorders to cancers and degenerative diseases.
The global cell and gene therapy market is witnessing unprecedented growth,…
ADC Cytotoxic Payloads and Warheads Driving the Next Wave of Targeted Cancer The …
The global Antibody-Drug Conjugate (ADC) Cytotoxic Payloads and Warheads Market is expanding rapidly as ADCs emerge as a cornerstone of targeted cancer therapy. ADCs combine the precision of monoclonal antibodies with the potency of cytotoxic drugs, enabling highly selective tumor targeting while minimizing systemic toxicity. At the heart of ADC technology are cytotoxic payloads and warheads-the active agents responsible for destroying cancer cells once delivered.
Download Full PDF Sample Copy of…
More Releases for Demyelinating
Chronic Inflammatory Demyelinating Polyneuropathy Market Current Trends, Challen …
The Chronic Inflammatory Demyelinating Polyneuropathy Market Is Set To Grow At An Estimated CAGR Of 6.9% From 2025 To 2034, Rising From $1.5 Billion In 2024 To $2.8 Billion By 2034.
On April 30, 2025, Exactitude Consultancy., Ltd. released a research report offers a comprehensive examination of the various processes and materials used in the production of Chronic Inflammatory Demyelinating Polyneuropathy market goods. The market study excludes key regions that are…
Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Therapeutics Assessme …
DelveInsight's, "Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Chronic Inflammatory Demyelinating Polyneuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Chronic Inflammatory…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Forayi …
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma…
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Outlook to 20 …
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses. Myelin acts as an insulation and allows efficient flow…
Chronic Inflammatory Demyelinating Polyneuropathy (CIPD) Treatment Market
Chronic inflammatory demyelinating polyneuropathy (CIPD) is an autoimmune disorder of the peripheral nervous system characterized by the weakness and impaired sensory function in the arms and legs. This disorder is caused by damage to the myelin sheath, a fatty covering that wraps and protects nerve fibers. The nerves stimulate muscle contraction and transmit sensory information to the brain through electrical impulses.
Myelin acts as an insulation and allows efficient flow…
Demyelinating Diseases Therapeutics Market By Key Trends and Analysis 2024
Demyelinating diseases are those diseases which affect the nervous system mostly damaging the myelin sheath of neurones. Thus, causing distortion of signals in the affected nerves which further leads to the deficiency in sensation, cognition, movements or impairing of any other physical function carried out by the affected nerve. In addition, demyelinating diseases are classified into two types demyelinating leukodystrophic diseases and demyelinating myelinoclastic diseases. Demyelinating diseases may occur due…
